Country: EU
Laboratories❯
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
Quality & Accuracy
Experience
The latest technologies
Speed &
Credibility
₾315.00
Study material: Venous blood
Response time (working day): 14
The test is done on an empty stomach: no
Home call service: YesSample submission day is Saturday
Sample collection will be carried out: in regional branches – on Monday. in Tbilisi branches – on Monday or Tuesday in the first half of the day.
sFlt-1/PlGF ratio Is a laboratory test used during pregnancy Preeclampsia To support developmental risk assessment and diagnostics.
Preeclampsia is a pregnancy complication characterized by With increased blood pressure and may be associated with dysfunction of various organs. Its development is associated with dysfunction of placental blood vessels and changes in the process of angiogenesis (the formation of new blood vessels).
sFlt-1 და PlGF Represents biomarkers produced by the placenta:
Placental growth factor PLGF The concentration in the first trimester is low, it starts to increase from 11-12 weeks. It reaches its peak by 30 weeks, after which the tendency to decrease again is observed.
sFLT-1 is elevated in preeclampsia.
sFLT-1/PLGF The ratio of angiogenic factors, together with the patient's anamnesis and ultrasound data, provides an opportunity to predict preeclampsia.
Long-term clinical studies have shown that pregnant women who will develop preeclampsia in the future have circulating sFLT-1Increase in concentration and PlGF A decrease in concentration, a few weeks before the development of preeclampsia. sFLT-1/PLGF The ratio is directly related to the severity of the disease.
Determining the severity of the disease
In hospitalized patients, it is often necessary to repeat the ratio in 48 hours. A sharp increase in the index indicates the worsening of the disease. If the indicator is unchanged, it indicates more or less stability of the situation. Verification is required no later than 2 weeks.
Study material: Venous blood
sFLT-1/PlGF Determining the ratio is informative in determining the need for hospitalization of pregnant women with hypertension, especially if:
Development of preeclampsia in the early stage of gestation (20-33 weeks + 6 days)
| sFlt-1/PIGFratio | Interpretation | Management |
| <38 | Exclusion of preeclampsia for a period of 4 weeks | In the absence of clinical signs, there is no need to clarify the test |
| 38-85 | Increased risk of preeclampsia | It is necessary to monitor and repeat the test in 1-2 weeks |
| > 85 | High probability of preeclampsia | It requires observation in the hospital and repeated testing in 2-4 days |
| > 655 | Very high risk of complications in the short term | Observation in the hospital, acceleration of childbirth |
The development of preeclampsia in the late stage of gestation (> 34week later)
| sFlt-1/PIGFratio | Interpretation | Management |
| <38 | Exclusion of preeclampsia for a period of 4 weeks | In the absence of clinical signs, there is no need to clarify the test |
| 38-110 | Increased risk of preeclampsia | It is necessary to monitor and repeat the test in 1-2 weeks |
| > 110 | High probability of preeclampsia | It requires observation in the hospital and repeated testing in 2-4 days |
| > 201 | Very high risk of complications in the short term | Observation in the hospital, acceleration of childbirth |
Risk factors for preeclampsia
Order all analyses online
Testing process
 |  |
| Purchase a test | Submission of material |
 |  |
| Results Online | Consult a doctor |
